Related Experiment Video

Updated: Aug 6, 2026

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells
09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers

Andrew J Deans1, Kum Kum Khanna, Carolyn J McNees

  • 1Trescowthick Research Laboratories, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.

Cancer Research
|August 17, 2006
PubMed

Insights

Cyclin-dependent kinase 2 (CDK2) inhibitors show promise in cancer therapy by enhancing DNA damage responses in checkpoint-deficient cells. This approach may improve treatments for cancers with DNA repair defects, like those involving BRCA1 mutations.

Area of Science:

  • Cell Biology
  • Molecular Oncology
  • Cancer Therapeutics

Background:

  • Abnormal cell cycle regulation by cyclin-dependent kinases (CDKs) is a key feature of cancer.
  • CDK inhibitors, especially for CDK2, have limited selective anti-cancer activity due to functional redundancy in cell cycle control.

Purpose of the Study:

  • To investigate a novel role for CDK2 in the DNA damage response.
  • To explore the therapeutic application of CDK inhibitors in cancer cells with deficient DNA damage checkpoints.

Main Methods:

  • Utilized CDK2-deficient mouse fibroblasts and CDK2 inhibition in human cancer cell lines (MCF7, U2OS) via siRNA and small molecules.
  • Assessed DNA damage signaling pathways (Chk1, p53, Rad51) and DNA repair efficiency using comet assays and cell-based assays for homologous recombination and nonhomologous end-joining.
  • Determined sensitivity of tumor cells with BRCA1 or ATM mutations to CDK inhibitors.

Main Results:

  • CDK2 inhibition delayed DNA damage signaling and impaired DNA repair, affecting both homologous recombination and nonhomologous end-joining.
  • Tumor cells with deficiencies in BRCA1 or ATM exhibited 2- to 4-fold increased sensitivity to CDK inhibitors.
  • CDK2 inhibition potentiated the effects of DNA-damaging agents in checkpoint-deficient cells.

Conclusions:

  • CDK2 inhibitors can selectively enhance cancer cell sensitivity to DNA-damaging agents like chemotherapy and radiotherapy.
  • CDK inhibitors represent a potential therapeutic strategy for cancers with defects in DNA repair pathways, including those with BRCA1 mutations.

More Related Videos

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging06:44

Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging

Published on: April 28, 2021

Two- and Three-Dimensional Live Cell Imaging of DNA Damage Response Proteins10:24

Two- and Three-Dimensional Live Cell Imaging of DNA Damage Response Proteins

Published on: September 28, 2012

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...